期刊文献+

Vav3对Lewis细胞增殖与凋亡影响观察 被引量:2

Effect of siRNA-mediated Vav3 silence on proliferation and apoptosis of Lewis lung carcinoma cells
原文传递
导出
摘要 目的:探讨Vav3调节Lewis肺癌细胞增殖及凋亡的作用及机制。方法:小分子干扰RNA(small interfering RNA,siRNA)下调Lewis肺癌细胞中Vav3蛋白的表达;蛋白质印迹法检测转染siRNA-Vav3后Vav3及JNK蛋白表达的变化;MTT方法检测细胞存活率,流式细胞仪检测细胞凋亡。结果:转染siRNA后,干扰组Vav3表达为0.154±0.024,较Lewis肺癌细胞组的0.417±0.073和对照组的0.383±0.049明显下调,F=22.052,P=0.002。下调Vav3表达后,干扰组JNK蛋白表达水平为0.619±0.008,与肺癌细胞组的1.251±0.117和对照组的1.192±0.092相比较明显下调,F=54.770,P<0.001。与肺癌细胞组细胞生存率(100.00±0.00)%和对照组(95.33±3.14)%相比,干扰组(75.87±2.30)%明显下降,P值分别为0.000 2和0.000 3。与肺癌细胞组细胞凋亡率(3.55±0.03)%和对照组(4.18±0.17)%相比,干扰组(12.16±0.02)%明显上升,P值分别为0.000 1和0.000 1。结论:下调Vav3表达,抑制Lewis肺癌细胞的增殖,并且促进肺癌细胞凋亡;Vav3发挥作用可能与JNK信号激活有关。 OBJECTIVE:To investigate the mechanism and effects of Vav3 on proliferation and apoptosis of Lewis lung carcinoma cells. METHODS:The small interfering RNA (siRNA) of Vav3 (siRNA-Vav3) was transfected into Lewis lung carcinoma ceils to inhibit the basal Vav3 level. The protein levels of Vav3 and JNK were detected by Western blot af- ter knockdown of endogenous Vav3. The cellular proliferation and apoptosis were analyzed by methylthiazolete trazolium (MTT) and flow cytometry(FCM), respectively. RESULTS: The Vav3 protein expression level of the experimental group, LLC group and control group was 0. 154 ± 0. 024,0. 417 ± 0. 073 and 0. 383 ± 0. 049, respectively after transient transfection of siRNA-Vav3. Analysis of variance showed that there was a significant difference among three groups (F= 22. 052,P=0. 002). JNK protein expression level of the experimental group, LLC group and control group was 0. 619 ± 0. 008,1.251± 0.117 and 0. 383 ± 0. 049, respectively after transient transfection of siRNA-Vav3. There was a significant difference among three groups(F= 54. 770, P〈0. 001). The survival rate of cells in expriment group(75.87± 2.30) was decreased than that in LLC group (100.00±0.00)% and in negative control group (95.33 ± 3.14)% (P= 0. 000 2, P=0. 000 3). In addition,the apoptosis rate of cells in expriment group (12.16±0.02)% was decreased compared to that in LLC group(3.55±0.03) % and in control group (4.18±0.17) %(P=0. 000 1 ,P=0. 000 1). CONCLUSION:It indica- ted that down-regulated expression of Vav3 protein can inhibit LLC cell proliferation and promote apoptosis of LLC cell, which may be related to the activation of JNK.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第5期333-336,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 黑龙江省卫生厅科研课题(2010-231)
关键词 Vav3 JNK 小干扰RNA LEWIS肺癌细胞 增殖 凋亡 Vav3 JNK small interfere RNA proliferation aapoptosisis
  • 相关文献

参考文献16

  • 1H omstein L, Alcover A, Katzav S, et al. Vav proteins,masters of the world of cytoskeleton organization[J]. Cell Signal, 2004,16 (1) :1-11.
  • 2Fujikawa K, Houe Y, Sakai M, et al. Vav3 is reguhted during the cell cycle and effects cell division[J]. Proc Natl Aead Sei U S A, 2002,99(7) :4313-4318.
  • 3王绍清,于秀文,赵春明,胡南.通过下调Lewis肺癌细胞Vav3基因的表达抑制细胞增殖[J].中国老年学杂志,2012,32(17):3726-3728. 被引量:5
  • 4Lomas A,Leonardi Bee J ,Bath-Hextall F,et al. A systematic re- view of worldwide incidence of non melanoma skin cancer[J]. Br J Dermatolin press,2013,11(7) :1069-1080.
  • 5Sauzeau V,Carvajal-Gonzdlez JM,Riolobos AS,et al. ranscriptional fac- tor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respir- atory functions by regulating the expression of the Vav3 proto-onco- gene[J]. J Biol Chem,2011,286(4):2896-2909.
  • 6Citterio C, Menacho-Marquez M, Garcia-Escudero R, et al. The Rho exchange factors Vav2 and Vav3 control a lung metastasis specific transcriptional program in breast cancer cetls[J]. Science Signaling,2012,5(244) :1-16.
  • 7Lin KY,Wang LH, Hseu YC, et al. Clinical significance of in creased guaninee exchange factor Vav3 expression in human gas- tric cancer [J]. Mol Cancer Res,2012,10(6) :750-759.
  • 8Peacock SO,Fahrenholtz CD,Burnstein KL,et al. Vav3 enhances androgen receptor splice variant activity and is critical for castra tion resistant prostate cancer growth and survival[J]. Mol Endo crinol,2012,26(12) :1967-1979.
  • 9王绍清,吴甜,帅智峰,董海影,张晓杰.Vav3表达下调对Lewis肺癌细胞体外侵袭能力影响的研究[J].中华肿瘤防治杂志,2013,20(10):737-740. 被引量:3
  • 10Nomura T, Yamasaki M, Hirai K, et al. Targeting the Vav3 on- cogene enhances docetaxel-induced apoptosis through the inhibi- tion of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia[J]. Mol Cancer, 2013, 12 (27) :1-15.

二级参考文献34

  • 1Takeda K, Stagg J, Yagita H, et al. Targeting death inducing receptors in cancer therapy[J]. Oncogene, 2007, 26 (25) : 3745- 3757.
  • 2Xu L, Qu X, Zhang Y, et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer ceils by CBL-regulated death receptor redistribution in lipid rafts[J]. FEBS Lett, 2009, 583 (5) :943-948.
  • 3Liu J, Qu X J, Xu L, et al. Bortezomib synergizes TRAIL-Induced apoptosis in gastric cancer cells[J]. Dig Dis Sci, 2010 Apr 15. [Epub ahead of print].
  • 4Weston C R, Davis R J. The JNK signal transduction pathway [J]. Curr Opin Cell Biol, 2007, 19(2) :142-149.
  • 5Noutomi T, Itoh M, Toyota H, et al. Tumor necrosis factor re lated apoptosis-indueing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells[J]. Oncol Rep, 2009, 22(5):1169-1172.
  • 6Mucha S R, Rizzani A, Gerbes A L, et al. JNK inhibition sensitises hepatocellular carcinoma ceils but not normal hepatocytes to the TNF-related apoptosis-inducing ligand[J]. Gut, 2009, 58 (5):688-698.
  • 7Ashkenazi A, Pai R C, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[J]. J Clin Invest, 1999, 104(2) :155-162.
  • 8Greco F A, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non- small cell lung cancer[J]. Lung Cancer, 2008, 61(1): 82-90.
  • 9Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosisin cancer[J]. Cancer Gene Therapy, 2005, 12(3): 228-237.
  • 10Liu J, Qu X, XU L, et al. Phosphoinositide 3 -kinase/Akt and nuclear factor kB pathways are involved in tumor necrosis factor related apoptosis-inducing ligand resistance in human gastric cancer cells[J]. Mol Med Rep, 2010, 3(3) :491- 496.

共引文献9

同被引文献25

  • 1Ross-Innes CS,Stark R,Teschendorff AE,et al.Differential oestrogen receptor binding is associated with clinical outcome in breast cancer[J].Nature,2012,481(7381):389-393.
  • 2Aguilar H,Urruticoechea A,Halonen P,et al.VAV3 mediates resistance to breast cancer endocrine therapy[J].Breast Cancer Res,2014,16(3):R53.
  • 3Sero NV,Delfino KR,Southey BR,et al.Cell cycle and aging,morphogenesis,and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival[J].BMC Med Genomics,2011,7(4):49-70.
  • 4Robinson DR,Wu YM,Vats P,et al.Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J].Nat Genet,2013,45(12):1446-1451.
  • 5Li S,Shen D,Shao J,et al.Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breastcancer-derived xenografts[J].Cell Rep,2013,4(6):1116-1130.
  • 6Ramaswamy B,Lu Y,Teng KY,et al.Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway[J].Cancer Res,2012,72(19):5048-5059.
  • 7Movilla N,Bustelo XR.Biological and regulatory properties of Vav-3,a new member of the Vav family of oncoproteins[J].Mol Cell Biol,1999,19(11):7870-7885.
  • 8Lee K,Liu Y,Mo JQ,et al.Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer[J].BMC Cancer,2008(8):158.
  • 9Dong Z,Liu Y,Lu S,et al.Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer[J].Mol Endocrinol,2006,20(10):2315-2325.
  • 10Citterio C,Menacho-Márquez M,García-Escudero R,et al.The rho exchange factors vav2 and vav3 control a lung metastasis-specifictranscriptional program in breast cancer cells[J].Sci Signal,2012,5(244):ra71.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部